Skip to main content
SpringerLink
Log in

A scoring system for predicting the survival prognosis of patients receiving stereotactic body radiation therapy (SBRT) for 1–3 lung metastases

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Introduction

The main goal of the present study was the development of a survival scoring system for patients treated with stereotactic body radiation therapy (SBRT) for very few lung metastases. Such an instrument would be of value when selecting the optimal dose for individual patients with a limited number of pulmonary lesions.

Methods

Forty-six patients receiving SBRT for 1–3 lung metastases were retrospectively analyzed. The biologically effective dose plus nine characteristics [gender, age, performance score, interval from tumor diagnosis to SBRT, primary tumor type, additional (extra-pulmonary) metastases, major location of lung metastases, number of pulmonary lesions, and volume treated with SBRT] were evaluated. Characteristics significantly associated with the survival on Cox regression analysis were incorporated in the scoring system. Scoring points were received from 1-year survival rates divided by 10. Sums of these scoring points represented the scores for the individual patients.

Results

Survival rates at 1 and 2 years were 66 and 56 %, respectively. On Cox regression analysis, performance score (p = 0.025), the type of primary tumor (p = 0.013) and the additional metastases (p = 0.032) had a significant impact on survival. Scores for patients ranged from 15 to 25 points. Three groups were designed: 15 points, 16–20 points, and 21–25 points. One-year survival rates were 0, 52, and 83 %, respectively (p = 0.005); 2-year survival rates were 0, 52, and 66 %, respectively.

Conclusion

A survival scoring system for patients receiving SBRT for very few lung metastases was developed. This score allowed us to estimate the survival prognosis of these patients and can aid physicians when aiming to choose the optimal SBRT dose for individual patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ashworth AB, Senan S, Palma DA et al (2014) An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 15:346–355

    Article  PubMed  Google Scholar 

  2. Scorsetti M, Clerici E, Navarria P et al (2015) The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. Br J Radiol 88:20150111

    Article  PubMed  Google Scholar 

  3. De Rose F, Cozzi L, Navarria P et al (2016) Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients. Clin Oncol (R Coll Radiol) 28:13–20

    Article  Google Scholar 

  4. García-Cabezas S, Bueno C, Rivin E et al (2015) Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). Clin Transl Oncol 17:668–672

    Article  PubMed  Google Scholar 

  5. Wang Z, Kong QT, Li J et al (2015) Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. J Thorac Dis 7:407–412

    PubMed  PubMed Central  Google Scholar 

  6. Frakulli R, Salvi F, Balestrini D et al (2015) Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res 35:5581–5586

    CAS  PubMed  Google Scholar 

  7. Carvajal C, Navarro-Martin A, Cacicedo J et al (2015) Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. J BUON 20:158–165

    PubMed  Google Scholar 

  8. Hayes JT, David EA, Qi L et al (2015) Risk of pneumonitis after stereotactic body radiation therapy in patients with previous anatomic lung resection. Clin Lung Cancer 16:379–384

    Article  PubMed  Google Scholar 

  9. Janssen S, Kaesmann L, Rudat V et al (2016) Stereotactic body radiotherapy (SBRT) with lower doses for selected patients with stage I non-small-cell lung cancer (NSCLC). Lung 194:291–294

    Article  CAS  PubMed  Google Scholar 

  10. Joiner MC, Van der Kogel AJ (1997) The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG (ed) Basic clinical radiobiology. Oxford University Press, New York, pp 106–112

    Google Scholar 

  11. Rades D, Douglas S, Veninga T et al (2010) Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer 116:3670–3673

    Article  PubMed  Google Scholar 

  12. Dziggel L, Segedin B, Podvrsnik NH et al (2013) Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189:364–666

    Article  CAS  PubMed  Google Scholar 

  13. Qiu H, Katz AW, Chowdhry AK et al (2015) Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol, in press, PMID: 26270442

  14. Fode MM, Høyer M (2015) Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol 114:155–160

    Article  PubMed  Google Scholar 

  15. Kress MA, Collins BT, Collins SP et al (2012) Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors. Radiat Oncol 7:148

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Stefan Janssen, Lukas Kaesmann & Dirk Rades

  2. Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany

    Stefan Janssen

  3. Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, Saudi Arabia

    Volker Rudat

Authors
  1. Stefan Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lukas Kaesmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Rudat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dirk Rades
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Rades.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Janssen, S., Kaesmann, L., Rudat, V. et al. A scoring system for predicting the survival prognosis of patients receiving stereotactic body radiation therapy (SBRT) for 1–3 lung metastases. Lung 194, 631–635 (2016). https://doi.org/10.1007/s00408-016-9906-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-016-9906-z

Keywords

Search

Navigation